Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Surface Oncology Inc (SURF)

Surface Oncology Inc (SURF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 328,670
  • Shares Outstanding, K 40,677
  • Annual Sales, $ 15,360 K
  • Annual Income, $ -54,790 K
  • 60-Month Beta 2.10
  • Price/Sales 21.66
  • Price/Cash Flow N/A
  • Price/Book 3.81
Trade SURF with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.43
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.61
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +24.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.51 +7.58%
on 11/25/20
10.05 -19.60%
on 11/11/20
-0.43 (-5.05%)
since 11/03/20
3-Month
5.57 +45.06%
on 09/24/20
10.25 -21.17%
on 10/14/20
+1.68 (+26.25%)
since 09/03/20
52-Week
1.38 +485.51%
on 03/18/20
10.25 -21.17%
on 10/14/20
+6.08 (+304.00%)
since 12/03/19

Most Recent Stories

More News
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive...

SURF : 8.08 (-1.22%)
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials

Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose-limiting toxicities

SURF : 8.08 (-1.22%)
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug...

SURF : 8.08 (-1.22%)
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate...

SURF : 8.08 (-1.22%)
Surface Oncology to Present at the Cowen IO Next Summit

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief...

SURF : 8.08 (-1.22%)
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

SRF388 inhibits hepatocellular carcinoma tumor growth as a single agent in a preclinical model

SURF : 8.08 (-1.22%)
Zacks.com featured highlights include: Matson, Surface Oncology, Green Brick Partners, Merchants Bancorp and Herc Holdings

Zacks.com featured highlights include: Matson, Surface Oncology, Green Brick Partners, Merchants Bancorp and Herc Holdings

MATX : 58.70 (+1.22%)
HRI : 60.99 (+1.08%)
GRBK : 22.60 (+0.44%)
MBIN : 26.55 (-0.30%)
SURF : 8.08 (-1.22%)
5 Stocks With Recent Price Strength Under Severe Volatility

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

MATX : 58.70 (+1.22%)
HRI : 60.99 (+1.08%)
GRBK : 22.60 (+0.44%)
MBIN : 26.55 (-0.30%)
SURF : 8.08 (-1.22%)
Surface Oncology to Report SRF388 Preclinical Data at the Upcoming International Cytokine and Interferon Society's Cytokines 2020 Virtual Conference

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388,...

SURF : 8.08 (-1.22%)
Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences

Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences

DQ : 38.92 (-0.71%)
HRI : 60.99 (+1.08%)
SURF : 8.08 (-1.22%)
CSTL : 51.17 (+0.20%)
CVLG : 17.43 (-4.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 8.35
1st Resistance Point 8.22
Last Price 8.08
1st Support Level 7.99
2nd Support Level 7.91

See More

52-Week High 10.25
Last Price 8.08
Fibonacci 61.8% 6.86
Fibonacci 50% 5.82
Fibonacci 38.2% 4.77
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar